- Home
- SST vs ABP Comparison
SST vs ABP Comparison
Compare SST & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- ABP
- Stock Information
- Founded
- SST 2013
- ABP 2004
- Country
- SST United States
- ABP United States
- Employees
- SST N/A
- ABP N/A
- Industry
- SST Diversified Commercial Services
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- SST Consumer Discretionary
- ABP Health Care
- Exchange
- SST Nasdaq
- ABP Nasdaq
- Market Cap
- SST 57.3M
- ABP 17.2M
- IPO Year
- SST N/A
- ABP N/A
- Fundamental
- Price
- SST $8.36
- ABP $0.19
- Analyst Decision
- SST Strong Buy
- ABP Strong Buy
- Analyst Count
- SST 1
- ABP 1
- Target Price
- SST $10.00
- ABP $4.00
- AVG Volume (30 Days)
- SST 49.0K
- ABP 3.1M
- Earning Date
- SST 11-06-2025
- ABP 08-13-2025
- Dividend Yield
- SST N/A
- ABP N/A
- EPS Growth
- SST N/A
- ABP N/A
- EPS
- SST N/A
- ABP N/A
- Revenue
- SST $317,055,000.00
- ABP $183,000.00
- Revenue This Year
- SST N/A
- ABP N/A
- Revenue Next Year
- SST $12.20
- ABP N/A
- P/E Ratio
- SST N/A
- ABP N/A
- Revenue Growth
- SST N/A
- ABP 154.17
- 52 Week Low
- SST $2.90
- ABP $0.15
- 52 Week High
- SST $15.00
- ABP $11.19
- Technical
- Relative Strength Index (RSI)
- SST 60.63
- ABP 41.23
- Support Level
- SST $7.51
- ABP $0.16
- Resistance Level
- SST $9.00
- ABP $0.19
- Average True Range (ATR)
- SST 0.59
- ABP 0.02
- MACD
- SST 0.08
- ABP -0.00
- Stochastic Oscillator
- SST 73.11
- ABP 34.65
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.